Ivonescimab with chemotherapy for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) for people with advanced adenocarcinoma of the esophagus, stomach, or gastroesophageal junction. The drug is designed to help the immune system fight cancer. The study is for people who have not had prior treatment for stage IV disease and whose cancer is HER2 negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (not squamous cell).
- Your cancer must be HER2 negative.
- You must not have had prior treatment for stage IV cancer.
- Your disease must be measurable or evaluable by imaging or physical exam.
- You must have adequate bone marrow, liver, and kidney function.
- You must not have active brain metastases or leptomeningeal disease.
- You must not have had major surgery within 4 weeks before registration.
- You must not have had prior treatment with a PD-1 or PD-L1 inhibitor.
- You must not have uncontrolled high blood pressure.
- You must not have a history of bleeding problems or blood clots within the last 4 weeks.
- You must not have had non-infectious pneumonitis requiring treatment within 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether adding the drug ivonescimab to standard chemotherapy, given before and after surgery, helps shrink tumors and lower the chance of the cancer coming back in people with advanced stomach cancer that can be removed with surgery.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.